ArticleFrontiers in immunology2026
Serum immune profiling suggests overlap between IBD patients with joint complaints and patients with spondyloarthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) and spondyloarthritis (SpA) are strongly associated, and joint complaints are common in patients with IBD. However, it remains unclear whether joint complaints in IBD merely reflect non-specific symptoms, or whether they are associated with systemic immune features overlapping with SpA. Methods: Using a proximity extension assay, 92 inflammation-related proteins were quantified in serum samples of patients from two cohorts: (i) IBD patients without (n = 100) and with joint complaints (n = 155; of whom 15 with SpA), and (ii) 169 patients with chronic back pain of unknown origin at the rheumatology outpatient clinic, where diagnosis of SpA was confirmed (n = 85) or rejected after 2 years of follow-up. Serum samples were collected at baseline. Results: IBD patients without joint complaints from cohort (i) and confirmed axSpA patients from cohort (ii) showed distinct serum immune profiles, with 20 differentially abundant proteins. Among IBD patients with joint complaints, formal SpA diagnosis had limited additional impact on the serum immune profile, with only three differentially abundant proteins between those with and without SpA. Similarly, among patients with chronic back pain, serum immune profiles were largely concordant irrespective of subsequent axSpA diagnosis. Importantly, IBD patients with joint complaints differed from IBD patients without joint complaints, and several proteins increased in this comparison overlapped with proteins increased in axSpA. Conclusions: Joint complaints in IBD are associated with a modest but detectable shift in the circulating immune profile, partly overlapping with axSpA-associated proteins. In contrast, formal SpA diagnosis adds limited additional serum-protein separation among patients who already have joint symptoms. These findings suggest that joint complaints in IBD may mark a biologically relevant subgroup beyond current SpA classification, and support longitudinal studies to determine whether this subgroup has distinct clinical trajectories or treatment responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.